Revised Response Criteria for Malignant Lymphoma

American Society of Clinical Oncology (ASCO) - Tập 25 Số 5 - Trang 579-586 - 2007
Bruce D. Cheson1,2, Beate Pfistner1, Malik E. Juweid1, Randy D. Gascoyne1, Lena Specht1, Sandra J. Horning1, Bertrand Coiffier1, Richard I. Fisher1, Anton Hagenbeek1, Emanuele Zucca1, Steven T. Rosen1, Sigrid Stroobants1, Tim Lister1, Richard T. Hoppe1, Martin Dreyling1, Kensei Tobinai1, Julie M. Vose1, Joseph M. Connors1, Massimo Federico1, Volker Diehl1
1From the Division of Hematology/Oncology, Georgetown University Hospital, Washington, DC; University of Cologne, Cologne; Department of Nuclear Medicine, University of Iowa, Iowa City, IA; Department of Pathology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada; Department of Oncology and Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark; Division of Oncology and Department of Radiation Oncology, Stanford University, Stanford,...
2Georgetown University

Tóm tắt

Purpose

Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies.

Methods

The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations.

Results

New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided.

Conclusion

We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.

Từ khóa


Tài liệu tham khảo

10.1200/JCO.1999.17.4.1244

10.1023/A:1008332713631

Pfistner B, Diehl V, Cheson B: International harmonization of trial parameters in malignant lymphoma. Eur J Haematol Suppl July:53,2005-54,

10.1023/A:1008486928190

10.1200/JCO.2001.19.2.414

10.1182/blood-2002-12-3842

10.1093/annonc/mdf256

Jerusalem G, Beguin Y, Fassotte MF, et al: Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 86:266,2001-273,

10.1182/blood.V94.2.429

10.1023/A:1011169332265

10.1097/00006231-199901000-00004

10.1023/A:1008308129857

10.1182/blood.V98.10.2930

10.1046/j.1365-2141.2001.03147.x

10.1002/cncr.10336

10.1038/sj.bjc.6601561

10.1093/annonc/mdh426

10.1093/annonc/mdi272

10.1056/NEJMra050276

10.1200/JCO.2005.01.891

10.1182/blood-2005-01-0272

Hutchings M, Loft A, Hansen M, et al: Positron emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 91:482,2006-489,

Querellou S, Valette F, Bodet-Milin C, et al: FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol 15:759,2006-767,

Gallamini A, Rigacci L, Merli F, et al: Predictive value of positron emission tomography performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 91:475,2006-481,

10.1182/blood-2005-06-2252

10.1002/1097-0142(20010301)91:5<889::AID-CNCR1078>3.0.CO;2-5

10.1007/s002590050275

10.1016/S0002-9343(01)01117-2

Juweid ME, Stroobants S, Hoekstra OS, et al: Use of positron emission tomography for response assessment of lymphoma: Consensus recommendations of the Imaging Subcommittee of the International Harmonization Project in Lymphoma. J Clin Oncol 10.1200/JCO.2006.08.2305

10.1023/A:1008312726163

10.1182/blood-2002-09-2778

10.1002/cncr.21967

Lewis PJ, Salama A: Uptake of fluorine-18-flouorodeoxyglucose in sarcoidosis. J Nucl Med 35:1647,1994-1649,

10.1097/01.mnm.0000171781.11027.bb

Kostakoglu L, Coleman M, Leonard JP, et al: PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43:1018,2002-1027,

10.1093/annonc/mdl122

10.1200/JCO.2005.13.524

10.1182/blood.V99.7.2541

10.1200/JCO.2001.19.6.1600

10.1016/0140-6736(93)91409-F

10.1093/jnci/89.18.1350

10.1136/gut.52.11.1656

Copie-Bergman C, Capella C, Motta T, et al: Validation of the GELA scoring system for evaluating gastric biopsies from patients with MALT lymphoma following eradication of . Ann Oncol 16:v94,2005, (suppl 5; abstr 194)Helicobacter pylori

10.1200/JCO.1991.9.7.1196

10.1148/radiology.210.2.r99fe63483

Foltz LM, Song KW, Connors JM: Who actually detects relapse in Hodgkin lymphoma: Patient or physician. Blood 104 (part 1):853a,2004-854a, (abstr 3124)

10.1093/annonc/mdl049

10.1093/annonc/mdg011

10.6004/jnccn.2006.0021

10.6004/jnccn.2006.0025

10.1093/annonc/5.suppl_2.S67